Detecting serum and urine metabolic profile changes of CCl4‑liver fibrosis in rats at 12 weeks based on gas chromatography‑mass spectrometry

Gao,Jiarong; Qin,Xiu‑Juan; Jiang,Hui; Chen,Jin‑Feng; Wang,Ting; Zhang,Ting; Xu,Shuang‑Zhi; Song,Jun‑Mei

doi:10.3892/etm.2017.4668

Detecting serum and urine metabolic profile changes of CCl4‑liver fibrosis in rats at 12 weeks based on gas chromatography‑mass spectrometry

Authors:
- Jiarong Gao
- Xiu‑Juan Qin
- Hui Jiang
- Jin‑Feng Chen
- Ting Wang
- Ting Zhang
- Shuang‑Zhi Xu
- Jun‑Mei Song
View Affiliations

Affiliations: Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031, P.R. China, College of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031, P.R. China
Published online on: June 26, 2017 https://doi.org/10.3892/etm.2017.4668
Pages: 1496-1504
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver fibrosis is caused by liver injury induced by a number of chronic liver diseases, including schistosome infection, hepatitis infection, metabolic disease, alcoholism and cholestasis. The tissue damage occurring after injury or inflammation of the liver is a reversible lesion; however, liver fibrosis has become a worldwide problem and poses a threat to human health. The development of an effective drug for the prevention and treatment of liver fibrosis is ongoing and uses information from different occurrences of liver fibrosis. In the present study, carbon tetrachloride (CCl4)‑induced metabonomic changes in serum and urine at 12 weeks were analyzed using gas chromatography‑mass spectrometry (GC/MS) to investigate potential biomarkers. Liver fibrosis was induced in rats by subcutaneous injections of CCl4 twice a week for 12 consecutive weeks. Histopathological changes were used to assess the successful production of a CCl4‑induced liver fibrosis model. Serum and urine samples from the two groups were collected at 12 weeks. The metabolic profile changes were analyzed by GC/MS alongside principal component analysis and orthogonal projections to latent structures. Metabolic profile studies indicated that the clustering of the two groups could be separated and seven metabolites in serum and five metabolites in urine were identified. In serum, the metabolites identified included isoleucine, L‑malic acid, α‑copper, carnitine, hippuric acid, glutaric acid and glucose. In urine 2‑hydroxy butyric acid, isoleucine, N‑acetyl‑β‑alanine, cytidine and corticoid were identified. The present study demonstrated that the pathogenesis of liver fibrosis may be associated with the dysfunction of a number of metabolic pathways, including glucose, amino acid, P450, fatty acid, nucleic acid, water‑electrolyte and glutathione biosynthesis. Assessing potential biomarkers may therefore provide novel targets and theories for the innovation of novel drugs to prevent and cure liver fibrosis.

View Figures

View References

1	Zira A, Kostidis S, Theocharis S, Sigala F, Engelsen SB, Andreadou I and Mikros E: 1H NMR-based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl4 administration. Toxicology. 303:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
2	Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P, Lu Z, Gao S, Liao Y, Chen B and Yu F: Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation-a novel mechanism suppressing liver fibrosis. FEBS J. 281:88–103. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhang S, Wu J, Wang H, Wang T, Jin L, Shu D, Shan W and Xiong S: Liposomal oxymatrine in hepatic fibrosis treatment: Formulation, in vitro and in vivo assessment. AAPS PharmSciTech. 15:620–629. 2014. View Article : Google Scholar : PubMed/NCBI
4	Sun LL, Chang W, Jiao LQ, Cui X and Dong G: Hepatic fibrosis and supersonic shear imaging in patients with different etiological chronic hepatic diseases. J Biol Regul Homeost Agents. 30:761–765. 2016.PubMed/NCBI
5	Seo KW, Sohn SY, Bhang DH, Nam MJ, Lee HW and Youn HY: Therapeutic effects of hepatocyte growth factor-overexpressing human umbilical cord blood-derived mesenchymal stem cells on liver fibrosis in rats. Cell Biol Int. 38:106–116. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lee JE, Lee JM, Lee KB, Yoon JH, Shin CI, Han JK and Choi BI: Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis B viral infection using magnetic resonance elastography. Korean J Radiol. 15:210–217. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ozkurt H, Keskiner F, Karatag O, Alkim C, Erturk SM and Basak M: Diffusion weighted MRI for hepatic fibrosis: Impact of b-Value. Iran J Radiol. 11:e35552014.PubMed/NCBI
8	Lu Q, Luo Y, Yuan CX, Yan LN, Wu H and Zhang ZW: Ultrasound imaging of bridge vessel transplant used to reconstruct the tributary of middle hepatic vein in living donor liver transplantation. Sichuan Da Xue Xue Bao Yi Xue Ban. 38:529–531. 2007.(In Chinese). PubMed/NCBI
9	Duan J, Hu C, Luo S, Zhao X and Wang T: Microcomputed tomography with diffraction-enhanced imaging for morphologic characterization and quantitative evaluation of microvessel of hepatic fibrosis in rats. PLoS One. 8:e781762013. View Article : Google Scholar : PubMed/NCBI
10	Razek AA, Khashaba M, Abdalla A, Bayomy M and Barakat T: Apparent diffusion coefficient value of hepatic fibrosis and inflammation in children with chronic hepatitis. Radiol Med. 119:903–909. 2014. View Article : Google Scholar : PubMed/NCBI
11	Leeming DJ, Byrjalsen I, Jiménez W, Christiansen C and Karsdal MA: Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis-a serological evaluation. Liver Int. 33:439–447. 2013. View Article : Google Scholar : PubMed/NCBI
12	Manna SK, Thompson MD and Gonzalez FJ: Application of mass spectrometry-based metabolomics in identification of early noninvasive biomarkers of alcohol-induced liver disease using mouse model. Adv Exp Med Biol. 815:217–238. 2015. View Article : Google Scholar : PubMed/NCBI
13	Huang X, Shao L, Gong Y, Mao Y, Liu C, Qu H and Cheng Y: A metabonomic characterization of CCl4-induced acute liver failure using partial least square regression based on the GC/MS metabolic profiles of plasma in mice. J Chromatogr B Analyt Technol Biomed Life Sci. 870:178–185. 2008. View Article : Google Scholar : PubMed/NCBI
14	Gou X, Tao Q, Feng Q, Peng J, Zhao Y, Dai J, Wang W, Zhang Y, Hu Y and Liu P: Urine metabolic profile changes of CCl4-liver fibrosis in rats and intervention effects of Yi Guan Jian Decoction using metabonomic approach. BMC Complement Altern Med. 13:1232013. View Article : Google Scholar : PubMed/NCBI
15	Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C, et al: Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta. 743:90–100. 2012. View Article : Google Scholar : PubMed/NCBI
16	Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H and Shen X: GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem. 401:635–646. 2011. View Article : Google Scholar : PubMed/NCBI
17	Sun S, Dai J, Fang J, Gou X, Cao H, Zheng N, Wang Y, Zhang W, Zhang Y, Jia W and Hu Y: Differences of excess and deficiency zheng in patients with chronic hepatitis B by urinary metabonomics. Evid Based Complement Alternat Med. 2013:7382452013. View Article : Google Scholar : PubMed/NCBI
18	Feng B, Wu S, Liu F, Gao Y, Dong F and Wei L: Metabonomic analysis of liver tissue from BALB/c mice with D-galactosamine/lipopolysaccharide-induced acute hepatic failure. BMC Gastroenterol. 13:732013. View Article : Google Scholar : PubMed/NCBI
19	Yu K, Sheng G, Sheng J, Chen Y, Xu W, Liu X, Cao H, Qu H, Cheng Y and Li L: A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. J Proteome Res. 6:2413–2419. 2007. View Article : Google Scholar : PubMed/NCBI
20	Lin B, Zhang H, Lin Z, Fang Y, Tian L, Yang H, Yan J, Liu H, Zhang W and Xi Z: Studies of single-walled carbon nanotubes-induced hepatotoxicity by NMR-based metabonomics of rat blood plasma and liver extracts. Nanoscale Res Lett. 8:2362013. View Article : Google Scholar : PubMed/NCBI
21	Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, Zhang F and Xu G: Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta. 650:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
22	Ma J, Yu J, Su X, Zhu C, Yang X, Sun H, Chen D, Wang Y, Cao H and Lu J: UPLC-MS-based serum metabonomics for identifying acute liver injury biomarkers in Chinese miniature pigs. Toxicol Lett. 225:358–366. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chen B, Ye B, Zhang J, Ying L and Chen Y: RDW to platelet ratio: A novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One. 8:e687802013. View Article : Google Scholar : PubMed/NCBI
24	Frias M, Rodriguez-Cano D, Cuenca-López F, Macías J, Gordon A, Manzanares-Martín B, Pineda JA, Camacho Á, Torre-Cisneros J, Peña J, et al: HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. Pharmacogenomics J. Oct 25–2016.(Epub ahead of print). View Article : Google Scholar
25	Chheda TK, Shivakumar P, Sadasivan SK, Chanderasekharan H, Moolemath Y, Oommen AM, Madanahalli JR and Marikunte VV: Fast food diet with CCl4 micro-dose induced hepatic-fibrosis-a novel animal model. BMC Gastroenterol. 14:892014. View Article : Google Scholar : PubMed/NCBI
26	Gou X, Tao Q, Feng Q, Peng J, Sun S, Cao H, Zheng N, Zhang Y, Hu Y and Liu P: Urinary metabonomics characterization of liver fibrosis induced by CCl4 in rats and intervention effects of Xia Yu Xue Decoction. J Pharm Biomed Anal. 74:62–65. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sun H, Zhang AH, Zou DX, Sun WJ, Wu XH and Wang XJ: Metabolomics coupled with pattern recognition and pathway analysis on potential biomarkers in liver injury and hepatoprotective effects of yinchenhao. Appl Biochem Biotechnol. 173:857–869. 2014. View Article : Google Scholar : PubMed/NCBI
28	Giudetti AM, Stanca E, Siculella L, Gnoni GV and Damiano F: Nutritional and hormonal regulation of citrate and carnitine/acylcarnitine transporters: Two mitochondrial carriers involved in fatty acid metabolism. Int J Mol Sci. 17(pii): E8172016. View Article : Google Scholar : PubMed/NCBI
29	Demiroren K, Dogan Y, Kocamaz H, Ozercan IH, Ilhan S, Ustundag B and Bahcecioglu IH: Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clin Res Hepatol Gastroenterol. 38:63–72. 2014. View Article : Google Scholar : PubMed/NCBI
30	Muroya Y, Ito O, Rong R, Takashima K, Ito D, Cao P, Nakamura Y, Joh K and Kohzuki M: Disorder of fatty acid metabolism in the kidney of PAN-induced nephrotic rats. Am J Physiol Renal Physiol. 303:F1070–F1079. 2012. View Article : Google Scholar : PubMed/NCBI
31	Manco M and Nobili V: Beta-cell glucose sensitivity in patients with liver fibrosis. Gut. 57:10232008.PubMed/NCBI
32	Haukeland JW, Konopski Z, Linnestad P, Azimy S, Løberg E Marit, Haaland T, Birkeland K and Bjøro K: Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 40:1469–1477. 2005. View Article : Google Scholar : PubMed/NCBI
33	Zant R, Melter M, Beck D, Ameres M, Knoppke B and Kunkel J: Glucose metabolism and associated outcome after pediatric liver transplantation. Transplant Proc. 48:2709–2713. 2016. View Article : Google Scholar : PubMed/NCBI
34	Haraguchi M, Miyaaki H, Ichikawa T, Shibata H, Honda T, Ozawa E, Miuma S, Taura N, Takeshima F and Nakao K: Glucose fluctuations reduce quality of sleep and of life in patients with liver cirrhosis. Hepatol Int. 11:125–131. 2017. View Article : Google Scholar : PubMed/NCBI
35	Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, Satishchandran A and Szabo G: The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 64:1378–1387. 2016. View Article : Google Scholar : PubMed/NCBI
36	Araújo Júnior RF, Garcia VB, Leitão RF, Brito GA, Ede C Miguel, Guedes PM and de Araújo A: Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells. PLoS One. 11:e01488682016. View Article : Google Scholar : PubMed/NCBI
37	Wang H, Zhang Y, Wang T, You H and Jia J: N-methyl-4-isoleucine cyclosporine attenuates CCl -induced liver fibrosis in rats by interacting with cyclophilin B and D. J Gastroenterol Hepatol. 26:558–567. 2011. View Article : Google Scholar : PubMed/NCBI
38	Tajiri K and Shimizu Y: Branched-chain amino acids in liver diseases. World J Gastroenterol. 19:7620–7629. 2013. View Article : Google Scholar : PubMed/NCBI
39	Britton RS and Bacon BR: Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology. 41:343–348. 1994.PubMed/NCBI
40	Miyake M, Innami T and Kakimoto Y: A beta-citryl-L-glutamate-hydrolysing enzyme in rat testes. Biochim Biophys Acta. 760:206–214. 1983. View Article : Google Scholar : PubMed/NCBI
41	Kadotani A, Fujimura M, Nakamura T, Ohyama S, Harada N, Maruki H, Tamai Y, Kanatani A and Eiki J: Metabolic impact of overexpression of liver glycogen synthase with serine-to-alanine substitutions in rat primary hepatocytes. Arch Biochem Biophys. 466:283–289. 2007. View Article : Google Scholar : PubMed/NCBI
42	Burelle Y, Fillipi C, Péronnet F and Leverve X: Mechanisms of increased gluconeogenesis from alanine in rat isolated hepatocytes after endurance training. Am J Physiol Endocrinol Metab. 278:E35–E42. 2000.PubMed/NCBI
43	Volpe DA, Tobin GA, Tavakkoli F, Dowling TC, Light PD and Parker RJ: Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. Regul Toxicol Pharmacol. 68:297–303. 2014. View Article : Google Scholar : PubMed/NCBI
44	Bouthillier LP, Pushpathadam JJ and Binette Y: Study of the metabolism of 2-hydroxy-4-amino-butyric acid, a product of gamma-hydroxyglutamic acid decarboxylation. Can J Biochem. 44:171–177. 1966. View Article : Google Scholar : PubMed/NCBI
45	Gallagher EP, Gardner JL and Barber DS: Several glutathione S-transferase isozymes that protect against oxidative injury are expressed in human liver mitochondria. Biochem Pharmacol. 71:1619–1628. 2006. View Article : Google Scholar : PubMed/NCBI
46	Cai J, Gong R, Yan F, Yu C, Liu L, Wang W, Lin Y, Guo M, Li W and Huang Z: ZNF300 knockdown inhibits forced megakaryocytic differentiation by phorbol and erythrocytic differentiation by arabinofuranosyl cytidine in K562 cells. PLoS One. 9:e1147682014. View Article : Google Scholar : PubMed/NCBI
47	Masoumi A, Ortiz F, Radhakrishnan J, Schrier RW and Colombo PC: Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure? Heart Fail Rev. 20:283–290. 2015. View Article : Google Scholar : PubMed/NCBI
48	Queisser N, Happ K, Link S, Jahn D, Zimnol A, Geier A and Schupp N: Aldosterone induces fibrosis, oxidative stress and DNA damage in livers of male rats independent of blood pressure changes. Toxicol Appl Pharmacol. 280:399–407. 2014. View Article : Google Scholar : PubMed/NCBI